-acetylglutamate synthase activity by valproyl-CoA. J Hepatol 55:426-434, 2011
2) Albrecht J, Norenberg MD:Glutamine:A Trojan horse in ammonia neurotoxicity. Hepatology 44:788-794, 2006
3) Albrecht J, Zielinska M, Norenberg MD:Glutamine as a mediator of ammonia neurotoxicity:A clinical appraisal. Biochem Pharmacol 80:1303-1308, 2010
4) Beversdorf D, Allen C, Nordgren R:Valproate-induced encephalopathy treated with carnitine in an adult. J Neurol Neurosurg Psychiatry 61:211, 1996
5) Bohles H, Sewell AC, Wenzel D:The effect of carnitine supplementation in valproate-induced hyperammonaemia. Acta Paediatr 85:446-449, 1996
6) Carr RB, Shrewsbury K:Hyperammonemia due to valproic acid in the psychiatric setting. Am J Psychiatry 164:1020-1027, 2007
7) Chopra A, Kolla BP, Mansukhami MP, et al:Valproate-induced hyperammonemic encephalopathy:An update on risk factors, clinical correlates and management. Gen Hosp Psychiatry 34:290-298, 2012
8) Costell M, O'Connor JE, Grisolia S:Age-dependent decrease of carnitine content in muscle of mice and humans. Biochem Biophys Res Commun 161:1135-1143, 1989
9) Coulter DL:Carnitine deficiency in epilepsy:Risk factors and treatment. J Child Neurol 10 (Suppl 2):S32-S39, 1995
10) De Vivo DC, Bohan TP, Coulter DL, et al:L-carnitine supplementation in childhood epilepsy:Current perspectives. Epilepsia 39:1216-1225, 1998
11) Lheureux PER, Penaloza A, Zahir S, et al:Science review:Carnitine in the treatment of valproic acid-induced toxicity-what is the evidence? Critical Care 9:431-440, 2005
12) Llansola M, Erceg S, Hernandez-Viadel M, et al:Prevention of ammonia and glutamate neurotoxicity by carnitine:Molecular mechanisms. Metab Brain Dis 17:389-397, 2002
13) Nakajima Y, Ito T, Maeda Y, et al:Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS. Brain Dev 33:816-823, 2011
14) Norenberg MD, Rama Rao KV, Jayakumar AR:Ammonia neurotoxicity and the mitochondrial permeability transition. J Bioenerg Biomembr 36:303-307, 2004
15) Ohtani Y, Endo F, Matsuda I:Carnitine deficiency and hyperammonemia associated with valproic acid therapy. J Padiatr 101:782-785, 1982
16) Raby WN:Carnitine for valproic acid-induced hyperammonemia. Am J Psychiatry 154:1168-1169, 1997
17) Raja M, Azzoni A:Valproate-induced hyperammonaemia. J Clin Psychopharmacol 22:631-633, 2002
18) Rama Rao KV, Jayakumar AR, Norenberg MD:Ammonia neurotoxicity:Role of the mitochondrial permeability transition. Metab Brain Dis 18:113-127, 2003
19) Raskind JY, El-Chaar GM:The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother 34:630-638, 2000
20) Stanley CA:Carnitine deficiency disorders in children. Ann NY Acad Sci 1033:42-51, 2004
21) Sztajnkrycer MD:Valproic acid toxicity:Overview and management. J Toxicol Clin Toxicol 40:789-801, 2002